Metabolic effects and mechanism of action of the pan PPAR agonist Lanifibranor

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-03-13 DOI:10.1016/j.jhep.2025.03.003

Silvia Sabatini, Amalia Gastaldelli

{"title":"Metabolic effects and mechanism of action of the pan PPAR agonist Lanifibranor","authors":"Silvia Sabatini, Amalia Gastaldelli","doi":"10.1016/j.jhep.2025.03.003","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Conflict of interest</h2>AG reports consultancy/advisory boards fee for Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals; received lecture fees from Merck Sharp & Dohme, Novo Nordisk, Eli Lilly and Company. SS reports no conflicts of interests related to this manuscript.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Authors’ contributions</h2>S.S and A.G. equally contributed to the writing of the manuscript.Lanifibranor is a triple peroxisome proliferator-activated receptor (PPAR) agonist and is one of the new molecules under investigation for the treatment of MASH with significant fibrosis (F2/F3. Results from the Phase 2b NATIVE trial [1] showed a significant reduction of at least 2 SAF-A score points without worsening of fibrosis (primary endpoint) in 55% and 48% of patients treated with the once-daily doses of 1200 mg and 800</section></section><section><section><h2>Financial support</h2>Internal funds of the Institute of Clinical Physiology-CNR.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"32 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2025.03.003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Conflict of interest

AG reports consultancy/advisory boards fee for Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals; received lecture fees from Merck Sharp & Dohme, Novo Nordisk, Eli Lilly and Company. SS reports no conflicts of interests related to this manuscript.Please refer to the accompanying ICMJE disclosure forms for further details.

Authors’ contributions

S.S and A.G. equally contributed to the writing of the manuscript.Lanifibranor is a triple peroxisome proliferator-activated receptor (PPAR) agonist and is one of the new molecules under investigation for the treatment of MASH with significant fibrosis (F2/F3. Results from the Phase 2b NATIVE trial [1] showed a significant reduction of at least 2 SAF-A score points without worsening of fibrosis (primary endpoint) in 55% and 48% of patients treated with the once-daily doses of 1200 mg and 800

Financial support

Internal funds of the Institute of Clinical Physiology-CNR.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.